Measurement of Blood Thiamine Metabolites for Alzheimer's Disease Diagnosis  by Pan, Xiaoli et al.
EBioMedicine 3 (2016) 155–162
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch aperPMeasurement of Blood Thiamine Metabolites for Alzheimer's
Disease DiagnosisXiaoli Pan a,1, Guoqiang Fei a,1, Jingwen Lu a,1, Lirong Jin a, Shumei Pan a, Zhichun Chen a, Changpeng Wang a,
Shaoming Sang a, Huimin Liu a,WeihongHu b, Hua Zhang b, HuiWang c, ZhiliangWang c, Qiong Tan d, YanQin d,
Qunying Zhang e, XuepingXie f, Yong Ji g, Donghong Cui b, XiaohuaGu h, JunXu h, Yuguo Yu i,⁎, Chunjiu Zhong a,⁎
a Department of Neurology, Zhongshan Hospital, State Key Laboratory of Medical Neurobiology, Institutes of Brain Science & Collaborative Innovation Center for Brain Science, Fudan University,
Shanghai 200032, China
b The Key laboratory of Translational Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
c Regional Health Service Center of Xujiahui, Xuhui District, Shanghai 200030, China
d Shanghai Institute of Pharmaceutical Industry, Shanghai 200437, China
e Shanghai Haiwan Hospital, Shanghai 201418, China
f Department of Geriatrics, Fengcheng Branch, Shanghai Ninth People's Hospital Afﬁliated Shanghai Jiao Tong University School of Medicine, Shanghai 201411, China
g Department of Neurology, Huanhu Hospital, Tianjin 300074, China
h Department of Neurology, Brain Hospital afﬁliated to Nanjing medical university, Nanjing 210029, Jiangsu Province, China
i Center for Computational Systems Biology, School of Life Sciences, Fudan University, Shanghai 200433, China⁎ Corresponding authors.
E-mail addresses: yuyuguo@fudan.edu.cn (Y. Yu), zho
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.ebiom.2015.11.039
2352-3964/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 18 October 2015
Received in revised form 24 November 2015
Accepted 24 November 2015
Available online 26 November 2015Background: Brain glucose hypometabolism is an invariant feature and has signiﬁcant diagnostic value for
Alzheimer's disease. Thiamine diphosphate (TDP) is a critical coenzyme for glucosemetabolism and signiﬁcantly
reduced in brain and blood samples of patients with Alzheimer's disease (AD).
Aims: To explore the diagnostic value of the measurement of blood thiamine metabolites for AD.
Methods: Blood TDP, thiamine monophosphate, and thiamine levels were detected using high performance liquid
chromatography (HPLC). The study included the exploration and validation phases. In the exploration phase, the
samples of 338 control subjects and 43 AD patients were utilized to establish the models for AD diagnosis assayed
by receiver operating characteristic (ROC) curve, including the variable γ that represents the best combination of
thiaminemetabolites and age to predict the possibility of AD. In the validation phase, the values ofmodelswere fur-
ther tested for AD diagnosis using samples of 861 control subjects, 81 AD patients, 70 vascular dementia patients,
and 13 frontotemporal dementia patients.
Results: TDP and theγ exhibited signiﬁcant and consistent values for ADdiagnosis in both exploration and validation
phases. TDP had 0.843 and 0.837 of the areas under ROC curve (AUCs), 77.4% and 81.5% of sensitivities, and 78.1%
and 77.2% of speciﬁcities respectively in the exploration and validation phases. The γ had 0.938 and 0.910 of
AUCs, 81.4% and 80.2% of sensitivities, and 90.5% and 87.2% of speciﬁcities respectively in the exploration
and validation phases. TDP and the γ can effectively distinguish AD from vascular dementia (64.3% for TDP, 67.1%
for γ) and frontotemporal dementia (84.6% for TDP, 100.0% for γ).
Interpretation.
Themeasurement of blood thiaminemetabolites by HPLC is an ideal diagnostic test for ADwith inexpensive, easy
to perform, noninvasive merits.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Blood1. IntroductionWe still lack not only disease-modifying therapy but also ideal diag-
nostic tool for Alzheimer's disease (AD), a devastating neurodegenera-
tive disease. The ideal diagnostic tool for AD should be inexpensive,
easy to perform, and non-invasive, as deﬁned by the Ronald andngcj@163.com (C. Zhong).
. This is an open access article underNancy Reagan Research Institute in 1998 (The Ronald and Nancy
Reagan Research Institute of The Alzheimer's Association and National
Institute on AgingWorking Group's, 1998). Existing tests for AD diagno-
sis include themeasurement of β-amyloid and tau in cerebrospinal ﬂuid
(CSF), the analysis of brain amyloid plaques and glucose metabolism
by positron emission tomography, the evaluation of brain atrophy by
magnetic resonance imaging (Palmert et al., 1990; Price et al., 2005;
Rosenmann, 2012; Vigo-Pelfrey et al., 1995). Although they can increase
the certainty of ADdiagnosis, they have not been recommended for rou-
tine diagnosis in thenewADdiagnosis guideline (McKhannet al., 2011),the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2011).
Impaired cerebral glucose metabolism is an invariant feature of AD
and precedes the onset of clinical symptoms (Chen and Zhong, 2013;
Small et al., 1995; Reiman et al., 1996; Mosconi et al., 2008a; Chen et al.,
2010). Thiaminediphosphate (TDP), the active formof thiamine, is critical
for glucosemetabolism as a key coenzyme of three rate-limiting enzymes
of glucose catabolism (pyruvate dehydrogenase and α-ketoglutarate
dehydrogenase in the Krebs cycle, and transketolase in pentose phos-
phate pathway) (Zhao et al., 2009). The reduction in TDP level and activ-
ities of TDP-dependent enzymes has been demonstrated both in blood
and autopsied brain samples of a small number of AD patients (Gibson
and Blass, 2007; Butterworth and Besnard, 1990; Gibson et al., 1988;
Héroux et al., 1996; Gold et al., 1995; Mastrogiacoma et al., 1996;
Bettendorff et al., 1996). However, the diagnostic value of the measure-
ment of blood thiamine metabolites for AD has not been reported. Here,
we found that the measurement of blood thiamine metabolites using
high performance liquid chromatography (HPLC) ﬂuoroscopy exhibited
signiﬁcant performance for AD diagnosis with over 80% of sensitivity
and speciﬁcity, signiﬁcant capacities of differentiating AD from vascular
dementia (VaD) and frontotemporal dementia (FTD). It is an ideal test
for AD diagnosis with inexpensive, easy to perform, noninvasive merits.
2. Methods
2.1. Study and Subjects
This study was approved by the Committee on Medical Ethics of
Zhongshan Hospital, Fudan University. Informed consent was obtained
from all participating subjects.
The studywas designed into the exploration and validation phases. In
the exploration phase, the diagnostic models were established and their
diagnostic values for AD were preliminarily evaluated by receiver oper-
ating characteristic (ROC) curve using samples of 43 AD patients and
338 control subjects with cognitive ability in the normal range assayed
by the Mini-Mental Status Evaluation (MMSE) scoring. These samples
were collected from three centers (Shanghai Mental Health Center,
Haiwan Hospital and Regional Health Service Center of Xujiahui) from
January to May 2012. In the validation phase, the diagnostic values of
the models for AD were further tested using samples of 81 AD patients,
70 VaD patients, 13 FTD patients, and 861 control subjects collected
from other four hospitals (Zhongshan hospital, Fengcheng hospital,
Huanhu hospital, and BrainHospital afﬁliated toNanjingmedical univer-
sity) as well as the three hospitals in the exploration phase (Shanghai
Mental Health Center, Haiwan Hospital, and Regional Health Service
Center of Xujiahui) from June 2012 to December 2014.
All subjects received the MMSE scoring. Subjects with reduced
MMSE scores received further neurological examination and neuropsy-
chological evaluation including the Activity of Daily Living (ADL)
scoring, Clinical Dementia Rating (CDR), and Hamilton Depression
Rating Scales (HDR) by enquiring patients and his/her healthcare givers.
All patients had cranialMRI/CT scan and were diagnosed simultaneous-
ly by two neurologists and/or psychiatrists specialized in dementia
(Chunjiu Zhong, Guoqiang Fei, Lirong Jin, Weihong Hu, Rong Ji, Jun Xu
and Qunying Zhang) according to DSM-IV. All subjects were tested for
blood hemoglobin, hepatic and renal functions. AD patients were fur-
ther tested blood folate and vitamin B12 levels, and thyroid function.
The following subjects were enrolled: 1. AD patients: (1) with main
complaint of memory decline characterized by gradual onset and
continuing deterioration over one year; (2) with decreased MMSE
score (b26) and at least one other cognitive deﬁcit beyond memory
impairment; (3) with increased CDR score (≥0.5) and impairment in
the performance of daily activities; (4) without a sign of damage in
brain structure as assayed by cranial CT and/or MRI scans, except for
brain atrophy; (5) without a diagnostic clue of other neurological
disorders; (6) ≥65 years old. 2. VaD patients (Roman et al., 1993):(1) with two or more cognitive deﬁcits; (2) with acute or sudden
onset; (3) with focal neurological sign(s) consistent with the evidence
of stroke by cranial CT and/orMRI imaging. 3. Frontotemporal dementia
patients included frontal variant frontotemporal dementia and progres-
sive non-ﬂuent aphasia (McKhann et al., 2001): (1) early and progressive
change in personality or language; (2) causing signiﬁcant impairments in
social and occupational function; (3) with a gradual onset; (4) excluding
other neurological conditions or systematic diseases.
The following subjects were excluded from this study:
(1) Alzheimer's disease patients with reduced blood folate and vitamin
B12 levels, or thyroid dysfunction; (2) subjects with major disorders of
gastrointestinal tracts; (3) subjects with major depression (HDR over 7
scores); (4) subjects taking thiamine supplements within one month;
(5) subjects with chronic alcohol abuse.
2.2. Blood TDP, Thiamine Monophosphate (TMP) and Thiamine
Measurement
Blood TDP, TMP, and thiamine levels in all subjects were measured
using HPLC ﬂuoroscopy at a single center. The HPLC operators were
blind to participant information. The HPLC method for measuring TDP,
TMP and thiamine levels was essentially as previously described (Pan
et al., 2010). Brieﬂy, after fasting whole blood samples anticoagulated
with heparin were collected, 150 μl of the whole blood samples were
mixed immediately with equal volume of 7.4% perchloric acid in
a 1.5 ml of Eppendorf tube. The mixture was vibrated for 30 s for
deproteinization. After centrifugation at 10,000 rpm at 4 °C for 6 min,
the supernatant was collected and stored at−20 °C until assay within
two weeks. Thiamine and its phosphate esters were derivatized into
thiochromes using potassium ferricyanide and separated by gradient
elusion with a C18 reversed-phase analytical column (250 × 4.6 mm).
The derivatives were measured by HPLC ﬂuoroscopy (Agilent 1100,
Santa Clara, CA) with an excitation wavelength of 367 nm and an
emission wavelength of 435 nm. Blood TDP, TMP and thiamine levels
were quantiﬁed using standard samples of TDP, TMP, and thiamine
(Sigma-Aldrich, St. Louis, MO).
2.3. Apolipoprotein E Genotypes Analysis
Apolipoprotein E (APOE) alleles were detected using an ABI
real-time TaqMan SNP genotyping assay (ABI, Life Technologies,
Carlsbad, CA) according to the manufacturer's instructions. Puriﬁcation
of human genomic DNA was performed using a genome extraction kit
(TIANGEN, Beijing, China). All subjects were divided into two groups,
APOE ε4-positive group with ε2/ε4, ε3/ε4, or ε4/ε4 genotypes and
APOE ε4-negative group with ε2/ε2, ε2/ε3, or ε3/ε3 genotypes.
2.4. Statistical Analysis
The results were expressed asmean± SEM except for demographic
data (means ± SD). Statistical analyses were performed using the Sta-
tistical Package for the Social Sciences software version 18.0 (SPSS Inc.,
Chicago, IL). Kruskal–Wallis test, Pearson chi-square test or Fisher
exact probability test were used to compare demographic data among
groups of control subjects and AD, VaD, FTD patients. Covariance analy-
sis was used to compare TDP levels adjusted for age and hemoglobin
levels. Mann–Whitney U test or Kruskal–Wallis test was utilized to
compare TMP and thiamine levels among groups of control subjects
and AD, VaD, FTD patients as well as AD subgroups divided by the dis-
ease severity. Spearman's rank correlation analysis was utilized be-
tween the levels of thiamine metabolites and age or hemoglobin levels.
ROC analysis was utilized to evaluate the values of different param-
eters for AD diagnosis by assessing the area under the ROC curve (AUC),
sensitivity, and speciﬁcity. Cut-off pointwas determined bymaximizing
the sum of sensitivity and speciﬁcity. The parameters included TDP and
a new variable γ predicted the probability of logic (P) value for AD
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thiamine, and age. The variable γ was derived to identify the best
combination of multiple diagnostic biomarkers based on the following
equation: γ= (1/TDP)∗((TMP + 1)^(−0.01))∗((T + 1)^(1/6))∗Age^2
by MATLAB R14 (Mathworks, Natick, MA).
3. Results
3.1. Study Subjects
The detailed demographic data were listed in Table 1 and
Supplementary Fig. S1. Forty-three AD patients and 338 control subjects
were enrolled in exploration phase. There were no signiﬁcant differences
in gender ratio between the twogroups. ADpatientswere older than con-
trol subjects and had fewer years of education, decreased MMSE scores
and hemoglobin levels (all P b 0.001). The presence of APOE ε4 allele in
AD patients was signiﬁcantly higher than that in control subjects. In vali-
dation phase, 81 AD patients, 861 control subjects, 70 VaD patients, and
13 FTD patients were recruited. FTD patients included two patients with
progressive non-ﬂuent aphasia and 11 patients with frontal variant FTD.
There were no signiﬁcant differences in gender ratio among AD, VaD,
FTD, and control groups. Patients with AD and VaD were older than con-
trol subjects (Pb 0.001) and FTDpatients (P b 0.05). Decreased education-
al years and MMSE scores were observed in patients with AD, VaD, and
FTD as compared with control subjects (P b 0.001). The presences of
APOE ε4 alleles in AD and VaD patients were higher than that in control
subjects (P b 0.001 in AD; P b 0.05 in VaD).
3.2. Blood TDP, TMP, Thiamine Levels and Their Diagnostic Value for AD
Blood TDP levels in AD patients were signiﬁcantly lower as
compared with that in control subjects in the exploration phase
(85.02 ± 4.01 nmol/L, n = 43 in AD patients, vs. 117.70 ± 1.32 nmol/L,
n = 338 in control subjects, P b 0.001). TMP and thiamine contents in
AD patients were not signiﬁcant different with that in control subjects
(TMP: 4.83 ± 0.87 vs. 3.61 ± 0.14 nmol/L; thiamine: 4.88 ± 0.70 vs.
3.31 ± 0.16 nmol/L, both P N 0.05; Fig. 1A). Consistently, TDP contents
in AD patients were signiﬁcantly lower than that in control subjects,
VaD patients, and FTD patients in the validation phases (86.50 ± 2.30
nmol/L, n = 81 in AD, 118.30 ± 0.92 nmol/L, n = 861 in control,
117.60 ± 4.56 nmol/L, n = 70 in VaD and 132.70 ± 12.64 nmol/L, n
= 13 in FTD, P b 0.001). TMP levels had no signiﬁcant differences
among AD patients, control subjects, and FTD patients (AD: 10.84 ±
0.97 nmol/L, control: 9.85 ± 0.22 nmol/L, FTD: 9.60 ± 2.14 nmol/L,
P N 0.05). VaD patients exhibited a signiﬁcant reduction in TMP levelsTable 1
Characteristics of study subjects.
Characteristics
(mean ± SE)
Gender Age (years) Education
(years)
Male
(n, %)
Female
(n, %)
Exploration phase Control
(n = 338)
156
(46.15)
182
(53.85)
71.50 ± 0.30
(63–89)
10.62 ± 0.22
(0–16)
AD
(n = 43)
14
(32.56)
29
(67.44)
82.19 ± 1.13
(65–95)a
5.09 ± 0.71
(0–16)a
Validation phase Control
(n = 861)
411
(47.74)
450
(52.26)
71.98 ± 0.20
(63–91)
11.48 ± 0.13
(0–16)
AD
(n = 81)
35
(43.21)
46
(56.79)
79.67 ± 0.74
(66–101)b,c
7.16 ± 0.59
(0–16)b
VaD
(n = 70)
37
(52.86)
33
(47.14)
77.23 ± 0.90
(55–91)b,c
6.23 ± 0.58
(0–16)b
FTD
(n = 13)
5(38.46) 8(61.54) 59.31 ± 1.81
(45–70)b
5.69 ± 0.95
(0–12)b
a: compared with control in exploration phase, P b 0.001.
b: compared with control in validation phase, P b 0.001.
c: compared with FTD, P b 0.001.
d: compared with control, P b 0.05.
$ 23/69, 1 patient was unable to be determined; # 5/12, 1 patient was unable to be determine(5.71 ± 0.51 nmol/L) compared to AD patients and control subjects
(both P b 0.001). Thiamine levels had no signiﬁcant differences
among AD patients and control subjects, VaD and FTD patients (AD:
4.92 ± 1.04 nmol/L; control: 3.74 ± 0.13 nmol/L, VaD: 5.29 ± 0.99
nmol/L; FTD: 4.66 ± 1.23 nmol/L, P N 0.05, Fig. 1C).
According to data from the exploration phase,when TDPwasused as
a diagnostic biomarker, ROC analysis showed that AUC reached 0.843
(95% CI 0.774–0.911), with sensitivity of 77.4% and speciﬁcity of 78.1%,
when the cut-off point was set to 99.48 nmol/L. Further, γ gave better
diagnostic value, with AUC of 0.938 (95% CI 0.899–0.976), sensitivity
of 81.4%, and speciﬁcity of 90.5%, when the cut-off point was set to
75.97 (Fig. 1B).
In the validation phase, both TDP level and γ exhibited consistent
power for AD diagnosis as compared with that in the exploration
phase, with AUCs of 0.837 (95% CI 0.790 to 0.883) and 0.910 (95% CI
0.880 to 0.941), sensitivities of 81.5% and 80.2%, speciﬁcities of 77.2 and
87.2% when the cut-off points of TDP level and γ were 99.48 nmol/L
and 75.97, respectively (Fig. 1D).
VaD and FTD patients can be effectively distinguished from AD pa-
tients according the cut-off points of TDP and γ. TDP reached differenti-
ating rates of 64.3% for VaD and 84.6% for FTD. γ reached differentiating
rates of 67.1% for VaD and 100.0% for FTD.
3.3. Effect of the Disease Severity in AD Patients on Levels of Blood Thiamine
Metabolites
The MMSE scores had no signiﬁcant correlations with blood TDP
levels in both control subjects (r = 0.0518, P = 0.0731, n = 1199)
and AD patients (r = 0.0706, P = 0.4359, n = 124, Fig. 2A and B). To
further exclude the effect of the severity of cognitive impairment on
the levels of blood thiamine metabolites, we divided AD patients into
three subgroups, including, severe moderate, and mild cognitive im-
pairments, according to either their MMSE (MMSE b 10 in severe
subgroup n = 59, MMSE of 10 - 17 in moderate subgroup n = 42,
MMSE N 17 inmild subgroup n=23) or CDR scores (CDR= 3 in severe
subgroup n = 55, CDR = 2 in moderate subgroup n = 29, CDR ≤ 1 in
mild subgroup n= 40). No signiﬁcant differences in blood TDP and thi-
amine levels were observed among the three subgroups either divided
by MMSE scores (TDP: in severe subgroup: 84.90 ± 3.23, in moderate
subgroup: 84.01 ± 2.89, and in mild subgroup: 92.40 ± 4.69 nmol/L;
thiamine: in severe subgroup: 4.45 ± 0.59, in moderate subgroup:
3.36 ± 0.39, in mild subgroup: 8.90 ± 3.45 nmol/L, all P N 0.05) or
divided by CDR scores (TDP: in severe subgroup: 87.80 ± 3.10, in
moderate subgroup: 79.73 ± 3.34, and in mild subgroup: 88.03 ±
3.94 nmol/L; thiamine: in severe subgroup: 4.54 ± 0.63, in moderateMMSE scores Hemoglobin
(g/L)
APOE ε4
(n, %)
Folate
(ng/ml)
Vitamin B12
(pg/ml)
28.56 ± 0.07
(26–30)
133.80 ± 0.74
(83–169)
63 (18.64) – –
5.70 ± 0.98
(0–20)a
122.80 ± 1.55
(95–141)a
22 (51.16)a 6.88 ± 0.62
(3.01–20)
363.30 ± 25.77
(203.30–856.7)
28.73 ± 0.04
(26–30)
139.80 ± 0.44
(89–193)
186 (21.60) – –
12.07 ± 0.87
(0–25)b
127.1 ± 1.79
(90–159)b
38 (46.91)b 7.79 ± 0.50
(3.01–20)
516.50 ± 42.80
(210.00–2000)
8.15 ± 0.93
(0–25)b
125.90 ± 2.12
(87–170)b
23 (33.33)d,$ – –
7.08 ± 2.15
(0–23)b
130.70 ± 3.55
(118–148)
5 (41.66)# – –
d.
Fig. 1.Altered levels of blood thiaminemetabolites in ADpatients and their diagnostic values in the exploration and validation phases. A. Blood TDP levels in ADpatients were signiﬁcantly
reduced as compared with that in control subjects (P b 0.001). There were no signiﬁcant differences in TMP and thiamine contents between AD and control subjects (both P N 0.05). B.
Diagnostic performances of blood TDP and the variable γ= (1/TDP)∗((TMP + 1)^(−0.01))∗((T + 1)^(1/6))∗Age^2. TDP: AUC was 0.843, the sensitivity was 77.4%, and the speciﬁcity
was 78.1% when the cut-off point was set to 99.48 nmol/L; The variable γ: AUC was 0.938, the sensitivity was 81.4% and the speciﬁcity was 90.5% when the cut-off point was set to
75.97. C. In the validation phase, blood TDP levels in AD patients still were signiﬁcantly reduced as compared with that in control subjects as well as that in VaD patients and FTD patients
(all P b 0.001). Blood TMP levels in ADpatients were not signiﬁcantly different from that in control subjects and FTD patients (P N 0.05). TMP levels in VaD patients were signiﬁcantly lower
than that in AD and control subjects (P b 0.001). Thiamine levels in AD patients were not signiﬁcantly different from that in control subjects, VaD patients, and FTD patients (P N 0.05).
D. Diagnostic performances of blood TDP level and the variable γ in the validation phase. TDP: AUC was 0.837, the sensitivity was 81.5% and the speciﬁcity 77.2% when the cut-off
point was 99.48 nmol/L; The variable γ: AUC was 0.910, the sensitivity was 80.2% and the speciﬁcity was 87.2% when the cut-off point was 75.97.
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0.05). Importantly, TDP levels in the three subgroups still were signiﬁ-
cantly decreased as compared with that in control subjects (118.20 ±
0.76 nmol/L, P b 0.001, n= 1199). Blood TMP levels among AD patients
withMMSE scores b10 (6.39± 0.80 nmol/L) and of 10–17 (9.24± 1.52
nmol/L), as well as control subjects (8.09 ± 0.18 nmol/L) were not
signiﬁcantly different (P N 0.05). TMP levels in AD patients with
MMSE scores N17 (13.94 ± 1.64 nmol/L) were signiﬁcantly increased
as compared with that in control subjects (P b 0.001), and AD patients
with MMSE scores b10 (P b 0.001) and MMSE scores of 10–17 (P b
0.01). Blood TMP levels in AD subgroup with CDR score of ≤1
(12.56 ± 1.23 nmol/L) were signiﬁcantly increased as compared with
that in AD subgroups with CDR scores of 3 (6.00 ± 0.79 nmol/L, P b
0.001) and 2 (8.74 ± 2.02 nmol/L, P b 0.01), as well as control group
(P b 0.001, Fig. 2C and D).
In addition, we also divided AD patients into two subgroups accord-
ing to their ADL scores: the subgroup with ADL scores of ≥23 (n = 45)
and subgroupwithADL scores of b23 (n=79). No statistical differences
in TDP and thiamine levels were found between two subgroups (TDP:
85.73 ± 3.61 vs. 86.13 ± 2.47 nmol/L; thiamine: 4.50 ± 0.68 vs.
5.14 ± 1.07 nmol/L, both P N 0.05). Blood TDP levels in the two sub-
groups still were signiﬁcantly reduced as comparedwith that in control
group (P b 0.001). TMP levels in the subgroup with ADL b23 (10.53 ±
1.03 nmol/L) were signiﬁcantly increased as compared with that in
the subgroupwith ADL ≥23 (5.64± 0.80 nmol/L, P b 0.001) and control
subjects (P b 0.01, Fig. 2E).3.4. Effects of Age, the Presence of Apolipoprotein E ε4 Allele, and
Hemoglobin Contents on the Levels of Thiamine Metabolites
There was a very weak negative correlation between age and blood
TDP levels in control subjects (r =−0.0823, P= 0.0022) but not in AD
patients (r =−0.0001, P = 0.9988, Fig. 3A and B). To exclude the po-
tential effect of age on the levels of thiamine metabolites, we divided
AD patients and control subjects into four subgroups: under 70 years
(AD n = 13, control n = 596), 71–75 years (AD n = 16, control
n = 260), 76–80 years (AD n = 25, control n = 250), and over
80 years (AD n= 70, control n = 93). TDP levels in all AD subgroups
had no signiﬁcant differences (P N 0.05) but were signiﬁcantly re-
duced as compared with that in the age-matched control subgroups
(≤70 years old subgroup: 87.31 ± 5.54 vs. 119.90 ± 1.07 nmol/L;
71–75 years old subgroup: 90.49 ± 6.28 vs. 118.10 ± 1.63 nmol/L;
76–80 years old subgroup: 81.27 ± 3.87 vs. 116.70 ± 1.72 nmol/L;
over 80 years old subgroup: 86.40 ± 2.85 vs. 111.00 ± 2.60 nmol/L; all
P b 0.001, Fig. 3C). No signiﬁcant differences were found in TMP and
thiamine levels between all AD subgroups and the age-matched
control subgroups (TMP: ≤70 years old subgroup: 11.08 ± 3.59 vs.
8.29 ± 0.26 nmol/L, 71–75 years old subgroup: 11.58 ± 2.50 vs. 8.18 ±
0.42 nmol/L, 76–80 years old subgroup: 7.63 ± 1.48 vs. 7.36 ±
0.36 nmol/L, N80 year subgroup: 8.08 ± 0.85 vs. 8.58 ± 0.74 nmol/L,
all P N 0.05; thiamine: ≤70 years old subgroup: 8.28 ± 4.26 vs. 3.57 ±
0.14 nmol/L, 71–75 year subgroup: 8.09 ± 3.75 vs. 3.66 ± 0.22 nmol/L,
76–80 years old subgroup: 2.91 ± 0.41 vs. 3.84 ± 0.27 nmol/L,
Fig. 2. Effect of the disease severity on the levels of blood thiamine metabolites. A. There were no signiﬁcant correlations between blood TDP levels and MMSE scores in control subjects
(r = 0.0518, P = 0.0731, n = 1199). B. There were no signiﬁcant correlations between blood TDP levels and MMSE scores in AD patients (r = 0.0706, P = 0.4359, n = 124). C. Effects of
cognitive impairment evaluated byMMSE scores on the levels of thiaminemetabolites. D. Effect of cognitive impairment evaluated by CDR scores on the levels of thiaminemetabolites. E.
Effect of ADL scores on the measurement of thiamine metabolites.
159X. Pan et al. / EBioMedicine 3 (2016) 155–162N80 years old subgroup: 4.27 ± 0.50 vs. 3.23 ± 0.37 nmol/L, all P N 0.05;
all P N 0.05, Fig. 3D and E).
The frequency of APOE ε4 allele in AD patients was 48.39% (60/124).
This value was signiﬁcantly higher than that of 20.77% in control sub-
jects (249/1199, P b 0.001). However, the presence of APOE ε4 allele
did not affect the levels of TDP, TMP, and thiamine in either AD patients
(TDP: 83.37 ± 2.95 vs. 88.44 ± 2.80 nmol/L, TMP: 9.08 ± 1.15 vs.
8.45 ± 0.97 nmol/L, thiamine: 3.85 ± 0.48 vs. 5.90 ± 1.32 nmol/L, all
P N 0.05, APOE ε4-positive ADpatients n=60, APOE ε4-negative AD pa-
tients n = 64; Fig. 3F) or control subjects (TDP: 116.00 ± 1.65 vs.118.70 ± 0.86 nmol/L, TMP: 7.93 ± 0.39 vs. 8.13 ± 0.21 nmol/L,
Thiamine: 3.41 ± 0.23 vs. 3.68 ± 0.12 nmol/L, all P N 0.05, ε4-positive
subjects n = 249, ε4-negative subjects n = 950, Fig. 3G).
Blood hemoglobin levels signiﬁcantly correlated with blood TDP
levels in control subjects (r = 0.2133, P b 0.0001, Fig. 3H) and AD pa-
tients (r = 0.3233, P b 0.001, Fig. 3I). To minimize the potential effect
of hemoglobin levels on the levels of blood thiamine metabolites, we
divided AD patients and control subjects into two subgroups: those
with hemoglobin levels b120 g/L (AD patients n = 39, control subjects
n = 78) and with hemoglobin levels ≥120 g/L (AD patients n = 85,
Fig. 3. The effects of age, APOE ε4 allele, blood hemoglobin levels on the levels of blood thiaminemetabolites. A. Therewas aweakly negative correlation between blood TDP levels and age
in control subjects (r=−0.0823, P=0.0022, n=1199). B. Therewere no signiﬁcant correlations between TDP levels and age inADpatients (r=−0.0001, P=0.9988, n=124). C. Blood
TDP levels were signiﬁcantly reduced in all AD subgroups as compared with that in age-matched control subgroups. D. There were no signiﬁcant differences in blood TMP levels between
AD subgroups and age-matched control subgroups. E. There were no signiﬁcant differences in blood thiamine levels between AD subgroups and age-matched control subgroups. F. There
were no statistical differences in blood TDP, TMP and thiamine levels between APOE ε4-positive and negative AD patients. G. No statistical differences were observed in blood TDP, TMP
and thiamine levels between APOE ε4-positive andAPOE ε4-negative control subjects. H. Blood hemoglobin levelsweakly correlatedwith blood TDP levels in control subjects (r=0.2133,
P b 0.0001, n = 1199). I. Blood hemoglobin levels also showed a weakly correlation with blood TDP levels in AD patients (r = 0.3233, P = 0.0002, n = 124). J. Comparison of blood TDP,
TMP, and thiamine levels betweenADpatients and control subjects with hemoglobin levels under 120 g/L. K. Comparison of blood TDP, TMP, and thiamine levels between ADpatients and
control subjects with hemoglobin levels over 120 g/L.
160 X. Pan et al. / EBioMedicine 3 (2016) 155–162control subjects n = 1121). AD patients with hemoglobin levels
b120 g/L still exhibited a signiﬁcant reduction in blood TDP levels as
compared to control subjects (76.85 ± 3.63 vs. 106.30 ± 2.96 nmol/L,
P b 0.001). No signiﬁcant differences in blood TMP and thiamine levelswere observed between the two subgroups (TMP: 6.78 ± 0.99 vs.
5.60 ± 0.52 nmol/L; thiamine: 4.32 ± 0.68 vs. 3.76 ± 0.26 nmol/L,
both P N 0.05; Fig. 3J). Consistently, the similar results were observed
in subjects with hemoglobin levels ≥120 g/L (TDP: 90.18 ± 2.34 vs.
161X. Pan et al. / EBioMedicine 3 (2016) 155–162119.00 ± 0.78 nmol/L, P b 0.001; TMP: 9.67 ± 0.98 vs. 8.27 ±
0.19 nmol/L, P N 0.05; thiamine: 5.18 ± 1.01 vs. 3.61 ± 0.11 nmol/L,
P N 0.05; Fig. 3K).4. Discussion
In this work, we demonstrated that the alteration in the levels of
blood thiamine metabolites serves as a promising biomarker for AD di-
agnosis, with high sensitivity and speciﬁcity. In both exploration and
validation phases of our study, we found that AD patients had signiﬁ-
cantly reduced blood TDP levels as compared to control subjects
(Fig. 1A,C). Blood TDP level exhibited a signiﬁcant diagnostic value for
AD using ROC analysis in the exploration phase, with AUC of 0.843,
sensitivity of 77.4%, and speciﬁcity of 78.1% (Fig. 1B). Moreover, γ that
represents the best combination of the levels of thiamine metabolites
and age to predict the possibility of AD had an even higher diagnostic
performance, with AUC of 0.938, sensitivity of 81.4%, and speciﬁcity of
90.5% (Fig. 1B). Because the measurement of blood thiamine metabo-
lites by HPLC is noninvasive, inexpensive, and easy to perform and be
standardized, these ﬁndings meet the criteria of an ideal biomarker for
AD diagnosis, deﬁned as sensitivity and speciﬁcity over 80% by the
Ronald and Nancy Reagan Research Institute of the Alzheimer's Associ-
ation and the National Institute on Aging Working Group in 1998 (The
Ronald and Nancy Reagan Research Institute of The Alzheimer's
Association and National Institute on Aging Working Group's, 1998).
Importantly, these ﬁndings can be further veriﬁed using a large scale
of samples in the validation phase (Fig. 1D). Our study indicates the
effectiveness and reliability of the measurement of blood thiamine
metabolites by HPLC as an ideal tool for AD diagnosis.
Another important feature of good diagnostic biomarker is the abil-
ity to distinguish other diseases with similar symptomatology from the
targeted disease (Langa et al., 2004). VaD and FTD are common diseases
of non-AD-type dementia with many overlapping characteristics with
AD. A previous study in autopsied brains showed that 55% of patients
clinically diagnosed as VaD had signiﬁcant AD-type pathological alter-
ations (Victoroff et al., 1995). Our study showed that the alteration of
the levels in blood thiamine metabolites was an efﬁcient biomarker in
differentiating AD from VaD. Blood TDP levels in VaD patients were in
the same range as compared with that in control subjects but were sig-
niﬁcantly increased as comparedwith that in AD patients (Fig. 1C). Over
64% of VaD patients (64.3% for TDP cut-off point and 67.1% for γ cut-off
point) could be differentiated from AD patients. Considering the high
co-morbidity of VaD and AD, this is a signiﬁcant result. In addition, the
measurement of blood thiamine metabolites exhibited an excellent ca-
pacity of differentiating FTD fromAD,with differentiation rates reaching
84.6% for TDP and 100.0% for γ value. Combining the above results with
that of a previous study showing no changes in blood TDP levels in
Parkinson's disease patients, as compared with control subjects (Gold
et al., 1998), the altered levels of blood thiamine metabolites can serve
as a speciﬁc biomarker for AD diagnosis.
To exclude the effect of the disease severity on the levels of blood
thiamine metabolites by changes in life style in AD patients, we further
assayed whether the disease severity correlated with the levels of thia-
mine metabolites. We found no differences in blood TDP, TMP and thi-
amine levels among mild, moderate and severe AD patients based on
MMSE and CDR scores. Similarly, there were no signiﬁcant differences
in the levels of thiamine metabolites between two subgroups divided
by ADL scores. TDP levels in all subgroups of AD patients were still
signiﬁcantly reduced as compared with that in control subjects
(Fig. 2C–E), suggesting that the alteration of blood thiaminemetabolites
is an excellent marker of AD diagnosis, independent of the degree of
disease severity.
APOE ε4 allele is a risk factor for sporadic AD. However, our study
showed no signiﬁcant differences in the levels of thiamine metabolites
between APOE ε4-positive and ε4-negative AD patients and controlsubjects (Fig. 3F and G). The results indicate that the presence of APOE
ε4 allele does not affect the levels of blood thiamine metabolites.
We further examined the relationship between the levels of thia-
mine metabolites and age and blood hemoglobin levels. Blood TDP
levels exhibited a mildly gradual decrease with increased age in control
subjects (Fig. 3A). However, in all age subgroups examined, AD patients
still had signiﬁcantly lower TDP levels as compared to control subjects
(Fig. 3C–E). In addition, blood TDP levels signiﬁcantly correlated with
hemoglobin contents both in control subjects and AD patients (Fig. 3H
and I), consistent with it being mostly present in red blood cells.
When subjects were sub-grouped according to hemoglobin level, AD
patients still exhibited signiﬁcantly lower TDP levels in both groups
(Fig. 3J and K). Together, these results demonstrated that the measure-
ment of blood thiaminemetabolites is an effective and reliable biomark-
er for AD, independent of age and blood hemoglobin level.
Currently, the alterations of CSF Aβ42, tau, and phosphor-tau are
already accepted as biomarkers for AD diagnosis. CSF Aβ42 has 0.913
of AUC, 96.4% of sensitivity, and 76.9% of speciﬁcity. Tau has 0.831 of
AUC, 69.6% of sensitivity, and 92.3% of speciﬁcity. Phosphor-tau has
0.753 of AUC, 67.9% of sensitivity, and 73.1 of speciﬁcity (Shaw et al.,
2009). The diagnostic value CSF Aβ42 for AD is superior to that of
blood TDP whereas the values of CSF tau and phosphor-tau are similar
to that in blood TDP. The combination of APOE ε4, CSF Aβ42 and tau
can further improve the value for AD diagnosis, with 0.942 of AUC,
98.2% of sensitivity, and 79.5% of speciﬁcity (Shaw et al., 2009). This
phenomenon also is similar to our results, which the γ variable
reﬂecting the combination of age, TDP, TMP, and thiamine has better
efﬁciency for AD diagnosis.
Brain glucose metabolism closely correlates with cognitive impair-
ment in AD patients (Chen et al., 2010; Mosconi et al., 2008b). The im-
provement of brain glucose metabolism by the application of nasal
insulin has the effects of enhancing cognitive function and neuroprotec-
tion on AD patients (Reger et al., 2008; Craft et al., 2012; Hölscher,
2014). The pathogenic factor(s) of cerebral glucose hypometabolism
in AD may be modiﬁable targets. Previous studies from our and other
laboratories have demonstrated that thiamine deﬁciency enhances
brain amyloid deposit and cognitive impairment in the mouse models
by multiple pathophysiological pathways, including oxidative stress
(Karuppagounder et al., 2009) and elevated activities of β-secretase
(Zhang et al., 2011) and glycogen synthase kinase-3 (Zhao et al.,
2011). Thus, altered thiamine metabolism may contribute to cognitive
impairment and neurodegeneration by perturbingbrain glucosemetab-
olism and inducingmultiple pathogenic factors in AD, and is a potential
target for AD therapy. The previous studies have demonstrated the ben-
eﬁcial effects of benfotiamine, a liposoluble derivative of thiamine,
against AD through multiple pathways (Pan et al., 2010; Bozic et al.,
2015; Gibson et al., 2013). Thus, the novel therapeutic strategy for AD
that simultaneously targets at abnormal thiamine metabolism and
multiple AD disease-causing mechanisms may offer new hope for AD
therapy.
In summary, our results showed that the alteration in the levels of
blood thiamine metabolites serves as a promising biomarker for AD di-
agnosis with sensitivity and speciﬁcity over 80%, and can effectively
allow distinction of VaD and FTD from AD. Importantly, the detection
of blood thiamine metabolites by HPLC is noninvasive, simple to per-
form and be standardized, reliable, and inexpensive. The measurement
of blood thiamine metabolites fulﬁlls the criteria of an ideal tool for AD
diagnosis and is suitable for studies in large populations.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.11.039.
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